Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis
Status:
Recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of ATA188 as a
monotherapy in Parts 1 and 2, to determine the recommended Part 2 dose (RP2D) of ATA188 as
monotherapy in Part 1, and to evaluate the effect of ATA188 treatment on clinical disability,
as assessed by sustained Expanded Disability Status Scale (EDSS) improvement at 12 months in
Part 2 in participants with progressive forms of multiple sclerosis (MS) (primary progressive
multiple sclerosis [PPMS] and secondary progressive multiple sclerosis [SPMS]).